Novartis announced today that it is initiating the SURPASS trial, a head-to-head clinical trial of secukinumab (Cosentyx) versus a proposed biosimilar adalimumab (referencing Humira and being developed by Sandoz, a Novartis division) in patients with ankylosing spondylitis.
Novartis announced today that it is initiating the SURPASS trial, a head-to-head clinical trial of secukinumab (Cosentyx) versus a proposed biosimilar adalimumab (referencing Humira and being developed by Sandoz, a Novartis division) in patients with ankylosing spondylitis (AS). Secukinumab, a targeted biologic therapy that inhibits IL-17A—a cytokine involved in inflammation of entheses—plays a role in both AS and psoriatic arthritis (PsA).
The trial will be the largest randomized, controlled study of a biologic treatment in AS, and is a 1-year, parallel-group, 3-arm study. In the first arm, patients will receive 150 mg of secukinumab subcutaneously (SC); in the second arm, patients will receive 300 mg of SC secukinumab; in the third, patients will receive 40 mg of SC adalimumab. The study’s primary endpoint is the proportion of patients with no spinal radiographic structural progression at 2 years.
The SURPASS trial is part of a larger clinical program for secukinumab, which includes the EXCEED trial, a head-to-head clinical trial of secukinumab monotherapy versus reference Humira monotherapy in patients with PsA. The EXCEED trial is currently recruiting, and will assess the superiority of secukinumab in terms of the American College of Rheumatology 20% improvement criteria (ACR20) at 52 weeks as the primary endpoint.
"The EXCEED and SURPASS head-to-head trials are addressing important clinical questions solving residual uncertainty for patients with PsA and AS," said Robert Landewé, MD, PhD, professor of rheumatology in the Amsterdam Rheumatology and Clinical Immunology Center and Zuyderland Medical Center. "These data would add to the body of evidence to underline the benefit of different biologic pathways for physicians,” added Landewé.
News of the SURPASS trial follows the release of November 2017 data that supported switching from the reference Humira to Sandoz’s proposed adalimumab biosimilar. Phase 3 confirmatory data showed that there were no clinically meaningful differences in efficacy, safety, or immunogenicity between patients who switched between the reference drug and the biosimilar multiple times versus patients who received the biosimilar alone.
Despite the Sandoz adalimumab biosimilar’s potential to eventually capture a share of the market for Humira, Novartis’ Cosentyx has already become a top-selling medicine after its 2015 launch, having crossed the $1 billion sales threshold in 2016.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.